VIEWPOINTS

Paul Moss Shares Insights from RWE Inform Study from AstraZeneca at IDWeek 2023

Shots: Paul Moss Professor of Hematology and Deputy Head of the College of Medicine at the University of Birmingham, shares insights from the RWE INFORM study from AstraZeneca INFORM used record data from 12 million people in the UK to study the relative risk of severe COVID-19 infection in patients with immune suppression Even though…

December 18, 2023

Helen Yeh & Naim Shehadeh in a Stirring Conversation with PharmaShots, Highlight the Results from T2NOW Study

Shots: At the EASD, AZ announced positive results from the T2NOW P-III study that evaluated the efficacy and safety of Forxiga as an add-on treatment in children and adolescents with T2D receiving metformin, insulin, or both Helen Yeh, VP, CVRM Therapy Area Biopharmaceuticals Medical at AstraZeneca, and Naim Shehadeh, Professor of Endocrinology, Rambam Health Care…

December 11, 2023

Kylen Cieslak and Robert Ley Discuss the Expansion of Thermo Fisher Scientific’s Services Central in the US & EU

Shots: Kylen Cieslak, Senior Manager, Service Marketing, Thermo Fisher Scientific, and Robert Ley, Senior Strategic Product Manager, Thermo Fisher Scientific in a stirring conversation with PharmaShots Kylen and Robert highlighted the recent expansion of Thermo Fisher Scientific’s Services Central in the United States and Europe Services Central is an online platform intended to provide 24/7…

December 7, 2023

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Shots: Mohamed Eid, VP of Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, at Boehringer Ingelheim, in a stimulating conversation with PharmaShots sheds light on the recent approval of Jardiance for the treatment of adults with chronic kidney disease Jardiance’s EMPA Kidney P-III trial results demonstrated a 28% relative risk reduction vs placebo. Jardiance…

December 5, 2023

Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

Shots While sharing the details on Fasenra, Andrew highlights the unmet medical need in the healthcare sector as there’s only one approved treatment for EGPA With mepolizumab as the comparator drug for the trial, Andrew shares the positive results in achieving remission rates. Andrew sheds light on the unique mechanism of benralizumab that directly targets…

December 4, 2023

In an Insightful Conversation with PharmaShots, Betty Woo Highlights Thermo Fisher’s Cell Therapy Collaboration Program

Shots: Betty Woo, VP of Cell, Gene, and Advanced Therapies, Thermo Fisher Scientific discusses the evolution of ThermoFisher’s strategic collaboration with ArsenalBio Betty highlights the development of programmable autologous T cells for the treatment of cancer and the cell therapy collaboration program Betty believes that through innovation and partnership, they can tap into the full…

November 30, 2023

Moitreyee Chatterjee-Kishore, in an absorbing conversation with PharmaShots, shares the highlights of the SPOTLIGHT & GLOW study

Shots: Moitreyee Chatterjee-Kishore, HOD, Immuno-Oncology & Cancer Cell Therapy at Astellas shares insights from the P-III trials (SPOTLIGHT & GLOW) In SPOTLIGHT and GLOW, zolbetuximab and chemotherapy demonstrated improved PFS and OS vs placebo plus chemotherapy, yielding positive outcomes for patients with advanced gastric or GEJ cancer. Moitreyee highlights the ongoing clinical trials for the…

November 29, 2023

Michael Irizarry shares insights from the P-III clinical study of LEQEMBI, for the treatment of Alzheimer’s disease

Shots: Michael Irizarry, Senior VP of Clinical Research and Deputy Chief Clinical Officer, Alzheimer’s Disease and Brain Health at Eisai in a stimulating conversation with PharmaShots Michael shares insights from the P-III clinical study Clarity AD of LEQEMBI for the treatment of Alzheimer’s disease The study highlights that LEQEMBI treatment met the primary endpoint and…

November 27, 2023

Matthew G. Fishler Shares the Highlights of AVEIR DR, the World’s First Dual-Chamber Leadless Pacemaker System

Shots: Matthew G. Fishler, Chief Engineer and Director of Product Development Abbott’s Cardiac Rythm Management Business, in an insightful conversation with PharmaShots Matthew shares the highlights of the recently approved AVEIR Dr, the world’s first dual-chamber leadless pacemaker system for patients with slower-than-normal or abnormal heart rhythms Equipped with i2i™ communication technology, AVIER DR eliminates…

November 20, 2023

Jane Reed Highlights the Growing Dependence of NLP to Comply with the Regulatory Guidelines

Shots: In an invigorating conversation with PharmaShots, Jane Reed discusses the transition from document-driven to data-driven decision-making in the pharmaceutical industry Jane sheds light on the increasing dependence on AI and ML in regulatory affairs and how it helps pharma companies mitigate errors, discrepancies, and non-compliance Jane highlights the benefits of NLP in ensuring regulatory…

November 16, 2023